Omeros Corporation (OMER)
NASDAQ:OMER
Want to see OMER full AI Analyst Report?
OMER Stock Chart & Stats
$13.44
-$0.23(-2.31%)
At close: 4:00 PM EST
$13.44
-$0.23(-2.31%)
Day’s Range― - ―
52-Week Range$2.95 - $17.65
Previous CloseN/A
Volume193.12K
Average Volume (3M)1.55M
Market Cap
$735.33M
Enterprise Value$1.11B
Total Cash (Recent Filing)$135.32M
Total Debt (Recent Filing)$310.63M
Price to Earnings (P/E)8.6
Beta1.05
Next Earnings
Aug 12, 2026EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.30
Shares Outstanding72,375,360
10 Day Avg. Volume1,854,606
30 Day Avg. Volume1,552,322
Financial Highlights & Ratios
PEG Ratio3.32
Price to Book (P/B)-9.00
Price to Sales (P/S)0.00
P/FCF Ratio-9.39
Enterprise Value/Market Cap1.51
Enterprise Value/Revenue111.97
Enterprise Value/Gross Profit-903.55
Enterprise Value/Ebitda-10.62
Forecast
1Y Price Target
$40.00Price Target Upside197.62% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.2
Revenue Forecast (FY)$84.47M
Bulls Say, Bears Say
Bulls Say
First-to-market FDA Approval For YARTEMLEA (lectin Pathway Inhibitor)Regulatory exclusivity and first-in-class status create a durable commercial moat for TA‑TMA. As the only approved lectin‑pathway inhibitor, YARTEMLEA benefits from unmet clinical need, formulary positioning and prescriber preference, supporting sustained uptake and pricing leverage over multiple quarters.
Material Non-dilutive Funding Via Novo Nordisk CollaborationThe large upfront payment and milestone structure meaningfully extend runway without equity issuance. This non‑dilutive capital finances commercialization and R&D, reduces near‑term funding risk, and allows management to prioritize clinical programs and launch investments without immediate equity dilution.
Reimbursement Progress And Early Commercial Traction For YARTEMLEAPermanent J‑code and potential NTAP materially simplify billing and enhance hospital reimbursement, a structural access improvement. Combined with early Q1 net revenues and ordering by transplant centers, these milestones support broader adoption, steadier revenue conversion and a clearer path to product‑driven cash flow positivity.
Bears Say
Sustained Cash Burn And Negative Operating/free Cash FlowLarge negative operating and free cash flow indicates the business is not yet self‑funding and remains dependent on milestone payments or financing. Continued high cash outflows constrain runway, increase refinancing or milestone‑timing risk, and place structural pressure on sustaining commercial investment over coming quarters.
Negative Shareholders' Equity Despite Sharp Debt ReductionNegative equity signals a weakened capital base and limits financial flexibility over time. Even with much lower debt, persistent negative shareholders' equity can hinder future funding options, increase cost of capital, and reduce resilience to setbacks or higher-than-expected commercialization costs.
Earnings Volatility From Mark‑to‑market Adjustments And Remaining ConvertiblesLarge noncash derivative remeasurements produce significant reported earnings swings independent of operations. Coupled with remaining convertible note principal and rising interest expense, this structurally increases reported volatility and complicates forecasting, potentially affecting stakeholder confidence and financing terms.
Omeros News
OMER FAQ
What was Omeros Corporation’s price range in the past 12 months?
Omeros Corporation lowest stock price was $2.95 and its highest was $17.65 in the past 12 months.
What is Omeros Corporation’s market cap?
Omeros Corporation’s market cap is $735.33M.
When is Omeros Corporation’s upcoming earnings report date?
Omeros Corporation’s upcoming earnings report date is Aug 12, 2026 which is in 67 days.
How were Omeros Corporation’s earnings last quarter?
Currently, no data Available
Is Omeros Corporation overvalued?
According to Wall Street analysts Omeros Corporation’s price is currently Undervalued.
Does Omeros Corporation pay dividends?
Omeros Corporation does not currently pay dividends.
What is Omeros Corporation’s EPS estimate?
Omeros Corporation’s EPS estimate is -0.25.
How many shares outstanding does Omeros Corporation have?
Omeros Corporation has 72,375,360 shares outstanding.
What happened to Omeros Corporation’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Omeros Corporation?
Currently, no hedge funds are holding shares in OMER
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Omeros Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$40.00 (197.62% Upside)
$40.00 (197.62% Upside)
Blogger Sentiment
Neutral
OMER Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 13.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 2.4%
Last 30 Days ▲ 1.4%
Last 30 Days ▲ 1.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
206.88%
12-Months-Change
Fundamentals
Return on Equity
-54.39%
Trailing 12-Months
Asset Growth
21.69%
Trailing 12-Months
Company Description
Omeros Corporation
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS); and Phase II clinical trial to treat COVID-19. Its clinical programs also consist of PPAR? (OMS405) that is in Phase II to treat opioid and nicotine addiction; PDE7 (OMS527), which is in Phase I trial for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) that is in Phase I trial for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs also include GPR174 Inhibitors and Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various cancers; and G protein-coupled receptor targets for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.
OMER Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong positive commercial and regulatory momentum driven by the FDA approval and rapid early launch of YARTEMLEA, meaningful non-dilutive capital from the Novo Nordisk transaction, a solid cash position, and multiple pipeline and scientific milestones. Offsetting factors include an adjusted operating loss (excluding noncash items), earnings volatility from mark-to-market adjustments tied to convertible note derivatives, remaining convertible debt, and the early stage of commercial adoption with limited patient-level disclosure. On balance, the highlights around approval, early revenue, cash infusion, reimbursement progress (J-code and potential NTAP), and broad pipeline progress outweigh the near-term financial and volatility headwinds.View all OMER earnings summariesOMER Stock 12 Month Forecast
Average Price Target
$40.00
▲(197.62% Upside)
Technical Analysis
Aldeyra Therapeutics
―
Abeona Therapeutics
―
―
Foghorn Therapeutics
―
Neumora Therapeutics, Inc.
―
Ownership Overview
3.73% Insiders
7.92% Mutual Funds
7.49% Other Institutional Investors
69.62% Public Companies and
Individual Investors